Table 2 Studies contradicted to the promotion effect of ADSCs on breast cancer
Reference | Year | ADSCs origin | ADSCs surface marker | Results |
|---|---|---|---|---|
Sun et al. [117] | 2009 | Human breast fat | – | ADSCs reduced lung metastasis and inhibited the growth of human breast cancer cells by inducing apoptosis in mice model |
Zimmerlin et al. [115] | 2011 | Human Subcutaneous adipose tissue | – | ADSCs enhance the growth of active metastatic pleural effusion cells, but not resting tumor cells |
Kucerova et al. [116] | 2013 | Human lipoaspirates | CD44+CD73+CD90+CD105+ CD14−CD34−CD45− | ADSCs inhibited the proliferation of SKBR3 cells via SDF-1α/CXCR4 and increased chemosensitivity in a paracrine manner |
Trivanović et al. [108] | 2014 | Human breast (normal versus cancer-affected) and abdominal | CD44+CD73+CD90+CD105+ CD11a−CD33−CD45−CD235a− | ADSC-derived CM showed antiproliferative activity |
Wu et al. [119] | 2019 | Human lipoaspirates | – | ADSC-derived CM reduced cell viability by triggering apoptosis in MCF-7, MDA-MB231, and MDA-MB468 cells via ATM-Chk2-dependent DNA damage response |
Plava et al. [118] | 2020 | Breast adipose tissue of healthy donors, adipose tissue adjacent to pre-malignant lesions or malignant lesions or malignant lesions with BRCA mutation | CD90+ CD105+ CD73+ CD14- CD20− CD34− CD45− | Cancer-related ADSCs displayed a significant enhancement on the proliferation and metastasis of JIMT but exhibited a weak promotion effect on T47D and no effect on MDA231 |